Loading resource…

Pierre Bouzat, MD, PhD; Jonathan Charbit, MD; Paer-Selim Abback, MD; Delphine Huet-Garrigue, MD; Nathalie Delhaye, MD; Marc Leone, MD, PhD; Guillaume Marcotte, MD; Jean-Stéphane David, MD, PhD; Albrice Levrat, MD; Karim Asehnoune, MD, PhD; Julien
The PROCOAG randomized clinical trial was conducted in 12 French level I trauma centers to assess the impact of 4F-PCC on blood product consumption in patients experiencing traumatic hemorrhage. The trial involved a double-blind, randomized, placebo-controlled design, focusing on patients at risk of massive transfusion. The findings aim to inform optimal transfusion strategies in traumatic hemorrhage, an area where current practices are not well-defined.
No account needed